Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
Canadian Securities Exchange Approves Gold Runner Exploration's Option to Acquire the Golden Girl Property from the B-ALL Syndicate in British Columbia's Prolific Golden Triangle
Rio Silver Inc. Invites Investors to Meet Management at PDAC 2026, the World's Premier Mining Convention
